Skip to main content
ABBV
NYSE Life Sciences

AbbVie Finalizes $8.0 Billion Multi-Tranche Senior Notes Offering for Debt Repayment and General Corporate Purposes

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$224.67
Mkt Cap
$397.29B
52W Low
$164.39
52W High
$244.81
52W Position info
37% above low
Off High info
8.2% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ABBV sits 37% above its 52-week low of $164.39.

Summary

AbbVie finalized an $8.0 billion multi-tranche senior notes offering, with proceeds primarily used for debt repayment and general corporate purposes, strengthening the company's financial position.


Key Events · Financing and Capital Events · ABBV

  • Finalized $8.0 Billion Debt Offering

    AbbVie completed an offering of $8.0 billion in senior notes across seven tranches, with maturities ranging from 2028 to 2066.

  • Use of Proceeds

    Net proceeds of approximately $7.95 billion will be used to repay $2.0 billion outstanding under a 364-Day Delayed Draw Term Loan Facility and for general corporate purposes.

  • Multi-Tranche Structure

    The offering includes both senior floating rate notes due 2028 and various fixed-rate senior notes with interest rates from 3.775% to 5.650%.

  • Unsecured Obligations

    The notes are unsecured, unsubordinated obligations of AbbVie, ranking equally with existing and future unsecured debt.


Analysis · ABBV · Life Sciences

AbbVie has finalized the terms of its $8.0 billion multi-tranche senior notes offering, providing full details on the interest rates and maturities for each series. This offering, which represents a substantial capital raise, is primarily intended to repay $2.0 billion outstanding under an existing term loan facility and for general corporate purposes. The successful issuance of these notes, priced close to par, demonstrates strong market access for AbbVie and enhances its financial flexibility by managing debt maturities and providing capital for future operations. This filing formalizes the detailed terms of the offering previously announced as finalized on February 25, 2026.

At the time of this filing, ABBV was trading at $224.67 on NYSE in the Life Sciences sector, with a market capitalization of approximately $397.3B. The 52-week trading range was $164.39 to $244.81. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABBV - Latest Insights

ABBV
Jul 23, 2026, 4:59 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $255.46
Real-time Price: $255.46 info
Change: $0 (0%) info
Market Cap: $453.924B info
ABBV
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $256.94
Real-time Price: $255.46 info
Change: -$1.48 (-0.57%) info
Market Cap: $453.924B info
ABBV
Jul 17, 2026, 8:37 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $256.86
Real-time Price: $255.46 info
Change: -$1.40 (-0.55%) info
Market Cap: $453.924B info
ABBV
Jul 06, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $255.50
Real-time Price: $255.46 info
Change: -$0.040 (-0.02%) info
Market Cap: $453.924B info
ABBV
Jul 06, 2026, 1:45 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $256.48
Real-time Price: $255.46 info
Change: -$1.02 (-0.40%) info
Market Cap: $453.924B info